Regulatory Due Diligence for Medical Devices & IVDs
NKB Regovanta delivers structured, decision-grade Regulatory Due Diligence services that provide clear visibility into regulatory status, compliance maturity, approval dependencies, and hidden liabilities for medical technology investments and M&A transactions. Our assessments go beyond surface checklists, offering actionable intelligence that supports confident investment decisions, deal structuring, valuation adjustments, and post-transaction integration planning.
M&A / PE Deals
Pre-Acquisition Risk Audits
FDA & EU MDR
Global Dossier Verification
Valuation Modeling
Remediation Cost Translation
100-Day Roadmap
Post-Close Compliance Plan
Regulatory Due Diligence for Medical Devices Service Portfolio
Click on each audit module below to explore our detailed technical verification, risk analysis, and transaction-grade deliverables.
Classification & Scope Validation
Independent verification of medical device and IVD risk classifications, intended clinical use boundaries, and regulatory qualification across global target markets.
Approval Route & Dossier Verification
Rigorous audit of active and planned regulatory approvals (FDA 510(k)/PMA, EU MDR/IVDR CE Marks, UKCA, CDSCO, SFDA, TGA) against commercial marketed claims.
Submission Status & Commitments
Audit of active health authority submissions, open review questions, deficiency letters, annual regulatory filings, and mandated post-approval clinical commitments.
Approval Dependencies & Timelines
Identification of regulatory bottlenecks, pending transition deadlines (EU MDR/IVDR extensions), and clearance timelines impacting deal closing schedules and valuation.
What Sets NKB Regovanta Apart in Due Diligence
Global exposure, structured thinking, and execution-ready expertise for high-stakes healthcare transactions.
Cross-Market Global Regulatory Mastery
Direct subject-matter expertise spanning US FDA, EU MDR/IVDR, UK MHRA, India CDSCO, Saudi Arabia SFDA, Australia TGA, and Health Canada.
Comprehensive Device & IVD Coverage
Evaluation capabilities spanning software (SaMD/AI), electro-medical devices, active implants, sterile disposables, IVD reagents, and drug-device combination products.
M&A, Private Equity & Strategic Deal Experience
Extensive track record supporting private equity funds, venture capital firms, investment banks, corporate development teams, and strategic buyers.
Decision-Grade, Business-Actionable Intelligence
We translate complex regulatory non-compliances into tangible deal terms, purchase price adjustments, escrow holdbacks, and practical remediation timelines.
Actionable Due Diligence Reports for Investors, Acquirers & Strategic Buyers
In medical device transactions, undiscovered regulatory gaps can lead to severe post-closing disruptions, mandatory product recalls, unexpected Notified Body audit suspensions, or multi-million-dollar remediation costs. Each NKB Regovanta due diligence engagement provides an exhaustive written report containing risk stratification, market-wise clearance verification, approval dependencies, financial valuation impact assessments, and clear pre-close conditions and 100-day post-close remediation execution plans.
Identify Hidden Liabilities Before You Invest, Acquire, or Partner
Independent, Execution-Neutral Assessments
Completely objective regulatory audits free from internal corporate bias, providing investors and acquirers with unvarnished compliance realities.
Translation of Regulatory Exposure into Valuation Impact
Quantifying the financial cost, engineering effort, and commercial delay required to remediate technical dossiers, QMS gaps, or inspection findings.
Market-Wise, Approval-Focused Visibility
Detailed mapping of target company product lines across global jurisdictions to identify true market readiness versus aspirational regulatory projections.
Practical Pre-Close & Post-Transaction Roadmaps
Delivering actionable closing conditions, reps & warranties input, escrow structuring recommendations, and 100-day post-close compliance execution plans.
Explore Related Regulatory Services
Global regulatory strategy, technical documentation, and quality audit capabilities
Frequently Asked Questions: Regulatory Due Diligence
When is regulatory due diligence needed for medical device and IVD companies?
Regulatory due diligence is essential during mergers and acquisitions (M&A), private equity buyouts, venture capital investments, corporate licensing agreements, distributor evaluations, and joint venture partnerships. It is conducted during the confirmatory due diligence phase before deal closing to uncover hidden non-compliances, misclassified devices, vulnerable approvals, unresolved FDA 483 observations, or looming EU MDR/IVDR transition liabilities that could impact valuation or disrupt commercial operations.
What does NKB Regovanta's regulatory due diligence report cover?
Our due diligence deliverables provide comprehensive, decision-grade intelligence: (1) Product classification and intended use validation; (2) Global approval verification and dossier completeness audits; (3) Quality Management System (ISO 13485 / FDA QMSR) maturity; (4) Manufacturing site permits, facility inspection history, and CAPA logs; (5) Predicate device defensibility and regulatory precedent benchmarking; (6) Clinical evaluation (CER/PER) and evidence gap analysis; (7) Stratified regulatory risk classification (Critical, Major, Manageable); and (8) Quantitative valuation impact modeling with structured pre-close and post-close remediation action plans.
How does regulatory due diligence impact deal valuation and transaction terms?
Regulatory due diligence translates technical non-compliances into commercial and financial terms. For example, if a target company's flagship product requires remediation from legacy MDD to EU MDR, has unsupported clinical claims, or faces an imminent FDA inspection with open CAPAs, our report quantifies the required remediation budget, delayed market entry timelines, and revenue risk. Dealmakers use this intelligence to negotiate purchase price reductions, structure specific indemnity clauses, require special escrow holdbacks, or adjust closing conditions.
Does NKB Regovanta support post-transaction regulatory integration and remediation?
Yes. In addition to pre-transaction risk identification, NKB Regovanta authors detailed 100-day post-acquisition regulatory execution plans. Our team can directly execute remediation projects, including updating Design History Files (DHF), authoring EU MDR/IVDR technical documentation, closing open CAPAs, remediating FDA 483 observations, transferring regulatory licenses, and establishing harmonized global quality systems.
What are common 'red flags' uncovered during medical device regulatory due diligence?
Frequent critical findings include: products marketed outside cleared intended uses (off-label marketing exposure); outdated or unvalidated clinical evaluation reports lacking clinical data; critical supplier/contract manufacturer changes made without required regulatory filings; open FDA warning letters or unverified CAPAs; uncompleted EU MDR/IVDR transition requirements putting CE certificates at risk; unvalidated sterilization or software lifecycles; and inadequate post-market vigilance tracking.
How do you evaluate Software as a Medical Device (SaMD) and AI-driven products?
For digital health, SaMD, and AI/ML medical devices, our due diligence audits evaluate compliance with IEC 62304 software lifecycles, cybersecurity risk management (threat models, SBOM, vulnerability tracking), FDA cybersecurity premarket guidance, algorithm training dataset provenance, validation against clinical ground truth, and change control mechanisms for adaptive machine learning models.
How fast can NKB Regovanta deliver a comprehensive regulatory due diligence audit?
Recognizing the fast-paced nature of M&A and investment transactions, NKB Regovanta offers expedited due diligence timelines. Preliminary red-flag assessments and high-level findings are typically delivered within 5 to 7 business days following data room access, with the full, comprehensive written due diligence report and management briefing completed within 2 to 3 weeks.
Can NKB Regovanta perform sell-side regulatory vendor due diligence (VDD)?
Yes. For founders, corporate spin-offs, and private equity sponsors preparing a medical device asset for sale or capital raising, we perform Vendor Due Diligence (VDD). We audit the asset's regulatory files, identify compliance vulnerabilities in advance, assist in remediating documentation gaps, and author an independent, credible regulatory fact book that builds buyer confidence and prevents deal renegotiations during bidding.
Which global markets and regulatory frameworks are covered in your assessments?
Our due diligence team covers all major global regulatory jurisdictions: United States (FDA - 510(k), De Novo, PMA, 21 CFR Part 820/QMSR, 21 CFR Part 4), European Union (EU MDR 2017/745, EU IVDR 2017/746, Article 117), United Kingdom (MHRA, UKCA), India (CDSCO - Medical Device Rules 2017), Saudi Arabia (SFDA), Australia (TGA), Canada (Health Canada), Brazil (ANVISA), and Japan (PMDA).
How does NKB Regovanta ensure strict confidentiality during due diligence engagements?
We operate under strict non-disclosure agreements (NDAs) and clean-team protocols. Our senior partners handle all virtual data room (VDR) reviews through secure, encrypted systems, ensuring sensitive target company intellectual property, trade secrets, submission files, and transactional details are fully safeguarded.
Planning a Medical Device or IVD Acquisition or Investment?
Connect with NKB Regovanta's senior regulatory due diligence partners to evaluate target compliance, uncover hidden risks, and protect deal value.